Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib

Ann Hematol. 2019 Oct;98(10):2433-2436. doi: 10.1007/s00277-019-03787-8. Epub 2019 Aug 24.

Authors

Annie Pang¹, Rex Au-Yeung², Rock Y Y Leung², Yok-Lam Kwong³

Affiliations

¹ Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
² Department of Pathology, Queen Mary Hospital, Hong Kong, China.
³ Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.

PMID: 31446456
DOI: 10.1007/s00277-019-03787-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Humans
Leg / pathology
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / metabolism
Lymphoma, Large B-Cell, Diffuse* / pathology
Male
Middle Aged
Piperidines
Prednisone / administration & dosage
Pyrazoles / administration & dosage*
Pyrimidines / administration & dosage*
Rituximab
Skin Neoplasms* / drug therapy
Skin Neoplasms* / metabolism
Skin Neoplasms* / pathology
Vincristine / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
Piperidines
Pyrazoles
Pyrimidines
R-CHOP protocol
ibrutinib
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Adenine
Prednisone